ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Treatment-Naïve and Treatment-Experienced, Non-Cirrhotic Asian Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection

Inclusion Criteria: * Chinese, South Korean, and Taiwanese descent with full Chinese, South Korean, and Taiwanese parentage * Chronic hepatitis C virus (HCV) infection prior to study enrollment. * Screening laboratory result indicating HCV subtype 1b (GT1b) infection. * Per local standard practice, documented absence of cirrhosis. * Participant has never received antiviral treatment (including interferon \[IFN\]-based therapy \[alpha, beta or pegylated (peg)IFN\] with or without RBV) for HCV infection (treatment-naïve participant) or participant must have documentation that they met the definition of one of the following categories (treatment experienced participant): Non-responder or Relapser * Participant has plasma HCV RNA level \> 10,000 IU/mL at Screening. Exclusion Criteria: * HCV genotype performed during screening indicating unable to genotype or infection with any HCV genotype other than GT1b. * Positive test result at Screening for hepatitis B surface antigen (HBsAg), or hepatitis B virus DNA (HBV-DNA) \> Lower Limit of Quantification (LLOQ) if HBsAg negative, or anti-human immunodeficiency virus antibody (HIV Ab) positive. * Any current or past clinical evidence of cirrhosis. * Any primary cause of liver disease other than chronic HCV infection. * Screening laboratory analyses showing abnormal kidney, hepatic, or hematologic function. * Use of known strong inducers of cytochrome P450 3A (CYP3A) or strong inhibitors of cytochrome P450 3A (CYP2C8) within 2 weeks or within 10 half-lives, whichever is longer, of the respective medication/supplement prior to study drug administration.